Pfizer jab lowers infection risk by 93% in teens, Israelis find
Three-month study confirms Pfizer’s effectiveness against the deadly Delta variant
The launch of vaccinations for 12- to 17-year-olds on Wednesday coincided with new findings that the Pfizer/BioNTech vaccine significantly decreases symptomatic Covid-19 in adolescents.
The three-month study in Israel, an early leader in Covid-19 vaccinations, involved almost 189,000 adolescents, equally split between vaccinated and unvaccinated.
The study, between July and September, coincided with Israel’s fourth wave of Covid-19 infections, during which the Delta variant was the dominant strain — as it is in SA...